248 related articles for article (PubMed ID: 29457840)
1. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
[TBL] [Abstract][Full Text] [Related]
2. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
3. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
[TBL] [Abstract][Full Text] [Related]
4. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
Gulilat M; Keller D; Linton B; Pananos AD; Lizotte D; Dresser GK; Alfonsi J; Tirona RG; Kim RB; Schwarz UI
J Thromb Thrombolysis; 2020 Feb; 49(2):294-303. PubMed ID: 31564018
[TBL] [Abstract][Full Text] [Related]
5. Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation.
Nakagawa J; Kinjo T; Aiuchi N; Ueno K; Tomita H; Niioka T
Eur J Clin Pharmacol; 2023 Jan; 79(1):127-135. PubMed ID: 36399204
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.
Ueshima S; Hira D; Tomitsuka C; Nomura M; Kimura Y; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
AAPS J; 2019 Jun; 21(5):80. PubMed ID: 31236790
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
8. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation.
Cirincione B; Kowalski K; Nielsen J; Roy A; Thanneer N; Byon W; Boyd R; Wang X; Leil T; LaCreta F; Ueno T; Oishi M; Frost C
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):728-738. PubMed ID: 30259707
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
14. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
Wan Z; Guo L; Li P; Zhao Z; Xu B; Ren L; Yan Y; Liu H; Zhang Y; Liu L
J Clin Pharm Ther; 2020 Oct; 45(5):1159-1167. PubMed ID: 32562509
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
16. Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban.
Suzuki S; Yamashita T; Akao M; Okumura K
Eur J Clin Pharmacol; 2021 Nov; 77(11):1757-1758. PubMed ID: 34014337
[No Abstract] [Full Text] [Related]
17. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
[TBL] [Abstract][Full Text] [Related]
20. Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.
Jones MJ; Eudaley ST; Moye RA; Hodge TA; Nesbit RM; Franks AS
J Thromb Thrombolysis; 2020 Aug; 50(2):330-336. PubMed ID: 31902123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]